ECMO for COVID-19 vs Influenza A H1N1 Associated ARDS

Extracorporeal Membrane Oxygenation for COVID-19 and Influenza H1N1 Associated Acute Respiratory Distress Syndrome: a Multi-centre Retrospective Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05080933

Acronym

InfluCOV_ECMO

Enrollment

308

Registered

2021-10-18

Start date

2009-08-22

Completion date

2021-02-28

Last updated

2021-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, COVID-19, H1N1 Influenza

Brief summary

Objective: Veno-venous ECMO has been used as a rescue therapy for patients with severe ARDS associated to influenza A H1N1 and COVID19 viral pneumonia. Little is known about outcome of these patients who required extracorporeal support. Research question: To compare outcome of patients who required VV ECMO for Covid19 and H1N1 associated ARDS

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Inclusion criteria

* COVID-19 or influenza A H1N1 (suspected or confirmed) diagnosis * Severe ARDS (according to Berlin Definition) * VV ECMO * Invasive mechanical ventilation through endotracheal tube or tracheostomy

Exclusion criteria

• Age\<18 years

Design outcomes

Primary

Measure	Time frame
All cause mortality on day 60 after ECMO initiation	60 days

Secondary

Measure	Time frame
Hospital length of stay	90 days
ICU length of stay	90 days
Hospital mortality on day 90 after ECMO initiation	90 days
ECMO duration	90 days
ECMO related mechanical complications	90 days
ECMO associated mechanical complications	60 days
Invasive mechanical ventilation duration	90 days
ECMO related haemorrhagic complications	90 days
ECMO associated hemorrhagic complications	60 days

Countries

Italy

Outcome results